medigraphic.com
ISSN 0185-6014 (Print)
Órgano oficial de difusión de la Federación Mexicana de Patología Clínica, AC y de la Asociación Latinoamericana de Patología Clínica/Medicina de Laboratorio

2007, Number 1

<< Back

Rev Mex Patol Clin Med Lab 2007; 54 (1)

Histological alterations at the pulmonary level induced by Mycoplasma fermentans

Román-Méndez C, Santellán-Olea MR, Cedillo-Ramírez L, Rivera-Tapia JA

Language: Spanish
References: 32
Page: 40-46
PDF size: 139.06 Kb.


ABSTRACT

Background: Mycoplasmas cause significant morbidity and mortality by pneumonia in humans and murine models. Objective: To evaluate the damage of Mycoplasma fermentans infection in respiratory tract. Hamsters were intratracheally inoculated with 106 CFU of Mycoplasma fermentans and sacrificed during 5, 15, 30, 60, 80 and 120 days postinoculation. Blood serum was obtained to detected antibodies against Mycoplasma fermentans by metabolic inhibition test. The lungs were removed aseptically to do the isolate in culture and histological study. Results: Serum anti-Mycoplasma fermentans antibodies titers were negative in all samples. Mycoplasma fermentans persisted in the respiratory tract for the entire 120 days studied and all hamsters became infected and developed histologic evidence of pulmonary inflammation. Mycoplasmas are primarily mucosal pathogens, living a parasitic existence in close association with epithelial cells of their host, usually in the respiratory or urogenital tracts. Animal models developed to investigate the potential role of mycoplasmas in chronic lung conditions, have also provide insight into the histopathological aspects of lung disease.


REFERENCES

  1. Razin S, Yogev D, Naot Y. Molecular biology and pathogenicity of mycoplasmas. Microbiol Mol Biol Rev 1998; 62: 1094-1156.

  2. Beccham MJ, Lo SC, Lewis DE, Comer SW, Riley KJ, Oldfield EC. Recovery from fulminant infection with Mycoplasma fermentans (incognitus strain) in non-immunocompromised host. Lancet 1991; 338: 1014-1015.

  3. Barry C. Mycoplasma interaction with the immune system: implications for disease pathology. Features 1996; 62: 471-475.

  4. Waites KB, Talkington D. Mycoplasma pneumoniae and its role as a human pathogen. Clin Microbiol Rev 2004; 17: 697-728.

  5. Stadtlander CTKH, Watson HL, Simecka JW, Cassell GH. Cytopathogenicity of Mycoplasma fermentans (including strain incognitus). Clin Infect Dis 1993; 17: (suppl 1): S289-301.

  6. Rivera-Tapia JA, Ramírez CL, Bermejo ZD, Giono CS. Papel de Mycoplasma fermentans en patologías gastrointestinales y su relación con la artritis reactiva. Rev Mex Patol Clin 2006; 53: 134-138.

  7. Ellison JS, Olson LD, Barile MF. Immunity and vaccine development. In: Maniloff J, Mc Elhaney RN, Finch LR, Baseman JB (eds). Mycoplasmas: molecular biology and pathogenesis. Washington, DC: American Society for Microbiology 1992; 491-499.

  8. Tryon VV, Baseman JB. Pathogenic determinants and mechanisms. In: Maniloff J, Mc Elhaney RN, Finch LR, Baseman JB (eds). Mycoplasmas: molecular biology and pathogenesis. Washington, DC: American Society for Microbiology 1992; 454-471.

  9. Rivera A, Yañez A, León G, Gil C, Giono S, Barba E, Cedillo L. Experimental arthritis induced by a clinical Mycoplasma fermentans isolate. BMC Muscul Dis “002; 3: 1-7.

  10. Baseman JB, Quackenbush LR. Preliminary assessment of AIDS-associated mycoplasma. ASM News 1990; 56: 319-323.

  11. Lo SC, Dawson MS, Wong DM. Identification of Mycoplasma incognitus infection in patients with AIDS: and immunohistochemical, in situ hibridization and ultrastructural study. Am J Trop Med Hyg 1989; 41: 601-616.

  12. Bauer FA, Wear JD, Angritt P, Lo SC. Mycoplasma fermentans (incognitus strain) infection in the kidneys of patients with acquired immunodeficiency syndrome and associated nephropathy. Human Pathol 1991; 22: 63-69.

  13. Chirgwin KD, Cummings CM, DeMeo LR, Murphy M, McCormack WM. Identification of mycoplasma in urine from persons infected with human immunodeficiency virus. Clin Infect Dis 1993; 17 (suppl 1): S264-266.

  14. Hakkerine K, Turanen M, Miettinem A, Karppelin M, Kaitila K, Jansson E. Mycoplasma and arthritis. Ann Rheum Dis 1992; 51: 1170-1172.

  15. Lo SC, Wear DJ, Green SL, Jones PG, Legier JF. Adult respiratory distress syndrome with or without systemic disease associated with infections due to Mycoplasma fermentans. Clin Infect Dis 1993; 17 (suppl 1): S259-263.

  16. Guide for care and use of laboratory animals USA. Department of Health and Human Services, National Institute of Health. NIH Publication 1985.

  17. Gabridge MG, Gerald DA, Murphy WH. Toxic membrane fraction from Mycoplasma fermentans. Infect Immun 1971; 4: 678-682.

  18. Lo SC, Wear DJ, Shin JWK, Wang RYH, Newton PB, Rodriguez JF. Fatal systemic infection of nonhuman primates by Mycoplasma fermentans (Incognitus strain) Clin Infect Dis 1993; 17 (suppl 1): S283-288.

  19. Bove JM. Molecular features of Mollicutes. Clin Infect Dis 1993; 17 (suppl 1): S10-31.

  20. Razin S. Adherence of pathogenic mycoplasmas to host cells. Biosci Rep 1999; 19: 367-372.

  21. Theiss PM, Karpas A, Wise KS. Antigenic topology of the P29 surface lipoprotein of Mycoplasma fermentans differential display of epitopes result in high-frequency phase variation. Infect Immun 1996; 64: 1800-1809.

  22. Theiss PM, Kim MF, Wise KS. Differential protein expression and surface presentation generates high-frequency antigenic variation in Mycoplasma fermentans. Infect Immun 1993; 61: 5123-5128.

  23. Dimitrov DS, Franzoso G, Salaman M, Blumenthal R, Tarshis M, Barile MF. Mycoplasma fermentans (Incognitus strain) cells are capable to fuse with T lymphocytes. Clin Infect Dis 1993; 17 (suppl 1): S305-308.

  24. Giron JA, Lange M, Baseman JB. Adherence, fibronectin and induction of cytoskeleton reorganization in cultured human cells by Mycoplasma penetrans. Infect Immun 1996; 64: 197-208.

  25. Brenner C, Neyrolles O, Blanchard A. Mycoplasma and HIV infection: from epidemiology to their interaction with immune cells. Frontiers in Bioscience 1996; 1: 42-54.

  26. Hardy RD, Jafri HS, Olsen K, Wordemann M, Hatfield J, Rogers BB, Patel P, Duffy L, Cassell G, McCracken GH, Ramilo O. Elevated cytokine and chemokine levels and prolonged pulmonary airflow resistance in a murine Mycoplasma pneumoniae pneumonia model: a microbiological, histological, immunologic, and respiratory plethysmographic profile. Infect Immun 2001; 69: 3869-3876.

  27. Shimizu T, Kida Y, Kuwano K. A dipalmitoylated lipoprotein from Mycoplasma pneumoniae activates NF-kB through TLR1, TLR2, and TLR6. J Immunol 2005; 175: 4641-4646.

  28. Hickman-Davis JD, McNicholas-Bevensee C, Davis IC, He-Ping M, Davis GC, Bosworth CA, Matalon S. Reactive species mediate inhibition of alveolar type II sodium transport during mycoplasma infection. Am J Respir Crit Care Med 2006; 173: 334-344.

  29. Parker LC, White MKB, Dower SK, Sabroe I. The expression and roles of toll-like receptors in the biology of the human neutrophils. J Leukoc Biol 2005; 77: 886-892.

  30. Cho HY, Jedlicka AE, Clarke R, Kleeberger SR. Role of toll-like receptor-4 in genetic susceptibility to lung injury induced by residual oil fly ash. Physiol Genomics 2005; 22: 108-117.

  31. Fabisiak JP, Gao F, Thomson RG, Strieter RM, Watkins SC, Dauber JH. Mycoplasma fermentans and TNF-² interact to amplify immune-modulating cytokines in human lung fibroblasts. Am J Physiol Lung Cell Mol Physiol 2006; 291: L781-L793.

  32. Gao F, Barchowsky A, Nemec AA, Fabisiak JP. Microbial stimulation by Mycoplasma fermentans synergistically amplifies IL-6 release by human lung fibroblasts in response to residual oil fly ash (ROFA) and nickel. Tox Sci 2004; 81: 467-479.




2020     |     www.medigraphic.com